Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 540 participants.
Also called NCT01956786
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 540 participants
- Sponsor
- Registry
-
NCT01956786
-
- Other papers using this trial's data
- Combined use of amlodipine and folic acid are significantly more efficacious than amlodipine alone in lowering plasma homocysteine and blood pressure among hypertensive patients with hyperhomocysteinemia and intolerance to ACEI: A multicenter, randomized, double-blind, parallel-controlled clinical trial
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT01956786. Randomized; quadruple masking; primary purpose treatment. Start 2013-09 (registry gives no type); primary completion 2013-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine
- Condition
- Essential Hypertension
- Intervention (Drug)
- Amlodipine-FA tablet,low dose group
- Intervention (Drug)
- Amlodipine-FA tablet,high dose group
- Intervention (Drug)
- Amlodipine
- Lead sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
- Collaborator
- Ruijin Hospital
- Collaborator
- Second Affiliated Hospital of Nanchang University
- Collaborator
- Xuzhou Medical University
Record details
- Record id
cardio:ct-nct01956786- Content hash
4c2f08b73e37e7d1a978d09a39403427d9a6c1762d76caf4bd5cc22726a86c06